A New Molecularly Targeted Therapeutic for Acute Myeloid Leukemia
The FDA approved a new molecularly targeted therapeutic for treating certain patients with acute myeloid leukemia (AML).
Progress Against Cancer
The FDA approved a new molecularly targeted therapeutic for treating certain patients with acute myeloid leukemia (AML).
The FDA approved a combination of two immunotherapeutics for treating patients with colorectal cancer.
The FDA approved two molecularly targeted therapeutics for use in combination to treat patients with metastatic melanoma.
The FDA approved a new anticancer therapeutic for treating certain patients with neuroendocrine tumors.
The FDA approved pembrolizumab for patients with recurrent or metastatic cervical cancer that tests positive for PD-L1 and that has progressed despite chemotherapy.
The FDA expanded the use of the immunotherapy pembrolizumab for certain patients with an aggressive type of non-Hodgkin lymphoma.
The FDA expanded the use of the CAR T-cell therapy tisagenlecleucel to include certain patients with non-Hodgkin lymphoma.
The FDA approved a combination of the immunotherapeutics to treat certain patients diagnosed with the most common form of kidney cancer.
The FDA approved a combination of molecularly targeted therapeutics for use in combination to treat patients with metastatic non-small cell lung cancer.
The May 2018 FDA approval of the immunotherapeutic durvalumab makes it the first treatment approved to reduce the risk of stage 3 lung cancer progressing.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More